Skip to main content
. 2019 Dec 20;12(1):28. doi: 10.3390/cancers12010028

Figure A2.

Figure A2

HROC87 PDX volumes. Volumes of HROC87 xenografts do not differ between the various treatment conditions. Moreover, there is considerable variation and hence in these animal experiments treatment differences do not really become apparent. This was the case in the left (A) as well as the right (B) flank. NC: untreated control, Gef: gefitinib, Vem: vemurafenib, Gef + Vem: combination-therapy with gefitinib and vemurafenib.